Fosfomycin as an alternative therapeutic option for treatment of infections caused by multi-resistant Gram-negative bacteria

• Autorzy: Zdzieblo M. , Andrzejczuk S. , Chudzik-Rzad B. , Juda M. , Malm A.
• Języki publikacji: EN

Abstrakty

EN

The problem of significantly reduced drug use concerns particularly the infections caused by multi-resistant pathogens, especially Gram-negative bacteria. In this regard, interest is increasing in the known for nearly 50 years, but now frequently forgotten antibiotic – fosfomycin. Fosfomycin possesses high effectiveness for multidrug-resistant bacteria, comprising of extended-spectrum β-lactamases (ESBL), Klebsiella pneumoniae carbapenemases (KPC); commonly, the pandrug-resistant (PDR) and the extensively drug-resistant (XDR) strains, especially from Enterobacteriaceae family. Because of facilitated distribution into inflamed tissues and a very broad range of in vitro bactericidal activity, fosfomycin may have various applications in the treatment of many kinds of bacterial infections, including acute uncomplicated infections of the urinary bladder or complicated urinary tract infections, urinary tract sepsis, pyelonephritis, cystitis, prostatitis and chronic lung infections in patients with cystic fibrosis, the great majority caused by multi-resistant Gram-negative bacteria, and in the therapy eradicating multidrug-resistant Helicobacter pylori. Fosfomycin may limit the toxicity of other antibiotics and play a protective role in the process of bacterial resistance development during the therapy. Combinations of different antimicrobials enable the use of forgotten antibiotics in commonly occurring infections, although they are still completely incurable.

Słowa kluczowe

EN

fosfomycin zob.phosphomycin; phosphomycin; phosphonomycin zob.phosphomycin; Monurol zob.phosphomycin; Monuril zob.phosphomycin; alternative option; therapeutic agent; treatment; infection; Gram-negative bacterium; cystic fibrosis; urinary tract; prostatitis; human disease

• Wydawca: -
• Czasopismo: Journal of Pre-Clinical and Clinical Research
• Rocznik: 2014
• Tom: 08
• Numer: 2
• Opis fizyczny: p.51-54,ref.

Twórcy

autor

Zdzieblo M.

• Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, 20-059 Lublin, Poland

autor

Andrzejczuk S.

• Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, 20-059 Lublin, Poland

autor

Chudzik-Rzad B.

• Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, 20-059 Lublin, Poland

autor

Juda M.

• Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, 20-059 Lublin, Poland

autor

Malm A.

• Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Medical University of Lublin, 20-059 Lublin, Poland

Bibliografia

• 1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant andpandrug-resistant bacteria: an international expert proposal for interimstandard definitions for acquired resistance. Clin Microbiol Infect.2012; 18(3): 268–281.
• 2. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. ‘Old’ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis. 2012;25(6): 626–633.
• 3. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, Woodruff HB, Mata JM, HernandezS, Mochales S. Phosphonomycin, a new antibiotic produced by strainsof Streptomyces. Science. 1969; 166: 122–123.
• 4. Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect. 2012; 18: 4–7.
• 5. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011; 15(11): 732–739.
• 6. Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa incystic fibrosis. J Cyst Fibros. 2003; 2(1): 19–24.
• 7. Jóźwik M. Skuteczność lecznicza preparatu MONURAL® w zwalczaniu zakażeń układu moczowego u kobiet. Gin Prakt. 2005; 87(6): 24–28(in Polish).
• 8. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, includingextended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010; 10(1): 43–50.
• 9. Gupta V, Rani H, Singla N, Kaistha N, Chander J. Determination of extended-spectrum β-lactamases and AmpC production inuropathogenic isolates of Escherichia coli and susceptibility tofosfomycin. J Lab Physicians. 2013; 5(2): 90–93.
• 10. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, Lázaro E, de Abajo FJ, Campos J. Parallel increase in community use of fosfomycinand resistance to fosfomycin in extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010; 65(11):2459–2463.
• 11. Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martinez-Ruiz R, Perez-Vazquez M, Alcaraz M, Garcia-Cobos S, Campos J. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 hasacquired resistance to fosfomycin. J Antimicrob Chemother. 2009;64(4): 712–717.
• 12. Lefort A, Chau F, Lepeule R, Dubée V, Kitzis MD, Dion S, Fantin B. Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase. Int J Antimicrob Agents. 2014; 43(4): 366–369.
• 13. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. Outcomesof critically ill intensive care unit patients treated with fosfomycin forinfections due to pandrug-resistant and extensively drug-resistantcarbapenemase-producing Gram-negative bacteria. Int J AntimicrobAgents. 2014; 43(1): 52–59.
• 14. Ho PL, Chan J, Lo WU, Lai EL, Cheung YY, Lau TC, Chow KH. Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichiacoli isolates. J Med Microbiol. 2013; 62(11): 1707–1713.
• 15. Tullio V, Cuffini AM, Banche G, Mandras N, Allizond V, Roana J, Giacchino F, Bonello F, Ungheri D, Carlone NA. Role of fosfomycintromethamine in modulating non-specific defence mechanisms inchronic uremic patients towards ESBL-producing Escherichia coli. IntJ Immunopathol Pharmacol. 2008; 21(1):153–160.
• 16. Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin,and tigecycline against multidrug-resistant Klebsiella pneumoniae,Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur JClin Microbiol Infect Dis. 2012; 31(5): 695–701.
• 17. Corvec S, Furustrand TU, Betrisey B, Borens O, Trampuz A. Activity of fosfomycin, tigecycline, colistin and gentamicin against extendedspectrum beta-lactamase-producing E. coli in a foreign-body infectionmodel. Antimicrob Agents Chemother. 2013; 57(3): 1421–1427.
• 18. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs. 2009; 69(14): 1879–1901.
• 19. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME.Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol. 2010; 66(4): 359–368.
• 20. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistantEnterobacteriaceae and multi-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011; 86(3): 250–259.
• 21. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE. Fosfomycin/tobramycinfor inhalation in patients with cystic fibrosis with pseudomonas airwayinfection. Am J Respir Crit Care Med. 2012; 185(2): 171–178.
• 22. UpToDate: Fosfomycin Drug Information. 2011. Available at: http:// www.uptodate.com.contents.fosfomycin-drug-information (accessed: 2014.07.12).
• 23. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents. 2003; 22(Suppl 2): 79–83.
• 24. Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistantorganisms. Antimicrob Agents Chemoter. 2012; 56(11): 5744–5748.
• 25. The Office for Registration of Medical Products, Medical Devices and Biocidal Products. en.urpl.gov.pl
• 26. Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, Frauman AG, Grayson ML. Is fosfomycin a potentialtreatment alternative for multidrug-resistant Gram-negative prostatitis?Clin Infect Dis. 2014; 58(4): 101–105.
• 27. Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® Inline Nebulizer System in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv. 2014; 27(6): 441– 448.
• 28. Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I. Helicobacter pylori susceptibility to fosfomycin,rifampin, and 5 usual antibiotics for H. pylori eradication. DiagnMicrobiol Infect Dis. 2014; 79(3): 358–361.
• 29. Barahona-Garrido J, Quiñonez NF, Cerda-Contreras E, Maria Sarti H, Téllez-Ávila FI. Fosfomycin-containing second-line treatment forHelicobacter pylori infection. Am J Gastroenterol. 2013;108(5): 858–859.
• 30. Polskie Towarzystwo Walki z Mukowiscydozą [Polish Association for Mucoviscidosis Control] http://www.ptwm.org.pl/ (access: 2014.01.07)(in Polish).
• 31. MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.J Antimicrob Chemother. 2009; 64(4): 829–836.
• 32. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010; 29(2): 127–142.54

Identyfikatory

DOI

10.5604/18982395.1135649